儿童和青少年肥胖筛查与体重管理干预:美国预防服务工作组证据报告与系统综述
本系统综述评估儿童青少年超重/肥胖筛查与治疗(行为、奥利司他、二甲双胍)的获益与危害,纳入42项生活方式干预试验(N=6956)及药物试验。接触≥26小时的生活方式干预在6-12个月持续降低 excess weight,二甲双胍与奥利司他相比安慰剂有更大BMI下降,但药物获益的临床意义不明确。
要点
- 无直接证据表明儿童青少年超重筛查的获益或危害。
- 接触≥26小时的生活方式干预可降低 excess weight,且无危害证据。
- 二甲双胍与奥利司他相比安慰剂有更大BMI下降,但临床意义不明确。
核心结论
- 接触≥26小时的生活方式减重干预可能有助于减少儿童和青少年的 excess weight。
- 药物使用的小幅获益的临床意义不明确。
研究设计与样本
- 系统综述纳入英文的筛查或治疗(行为、奥利司他、二甲双胍)获益或危害试验,对象为2至18岁超重或肥胖儿童,在医疗环境中开展或招募。
- 数据来源包括MEDLINE、PubMed、PsycINFO、Cochrane对照试验注册库、Education Resources Information Center,检索截至2016年1月22日,监测持续至2016年12月5日。
- 两名研究者独立审阅摘要和全文,从质量一般和良好的试验中提取数据,采用随机效应Meta分析估计生活方式项目和二甲双胍的获益。
主要发现
- 42项生活方式干预试验(N=6956)中,估计接触≥26小时的干预在6至12个月后相比常规护理或其他对照组持续显示 excess weight 平均减少,无危害证据。
- 干预组BMI z评分绝对降低通常≥0.20,体重维持在基线均值约5磅以内,而对照组BMI z评分小幅增加或无变化,通常平均增加5至17磅。
- 26项接触时间较少的干预中仅3项显示体重降低获益。
- 二甲双胍(8项研究,n=616)与奥利司他(3项研究,n=779)相比安慰剂与更大的BMI下降相关:二甲双胍为-0.86(95% CI,-1.44至-0.29;6项研究;I²=0%),奥利司他为-0.50至-0.94。
- 接受接触≥52小时生活方式干预的组相比对照组血压改善更大:收缩压-6.4 mm Hg(95% CI,-8.6至-4.2;6项研究;I²=51%),舒张压-4.0 mm Hg(95% CI,-5.6至-2.5;6项研究;I²=17%)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Obesity is common in children and adolescents in the United States, is associated with negative health effects, and increases the likelihood of obesity in adulthood. OBJECTIVE: To systematically review the benefits and harms of screening and treatment for obesity and overweight in children and adolescents to inform the US Preventive Services Task Force. DATA SOURCES: MEDLINE, PubMed, PsycINFO, Cochrane Collaboration Registry of Controlled Trials, and the Education Resources Information Center through January 22, 2016; references of relevant publications; government websites. Surveillance continued through December 5, 2016. STUDY SELECTION: English-language trials of benefits or harms of screening or treatment (behavior-based, orlistat, metformin) for overweight or obesity in children aged 2 through 18 years, conducted in or recruited from health care settings. DATA EXTRACTION AND SYNTHESIS: Two investigators independently reviewed abstracts and full-text articles, then extracted data from fair- and good-quality trials. Random-effects meta-analysis was used to estimate the benefits of lifestyle-based programs and metformin. MAIN OUTCOMES AND MEASURES: Weight or excess weight (eg, body mass index [BMI]; BMI z score, measuring the number of standard deviations from the median BMI for age and sex), cardiometabolic outcomes, quality of life, other health outcomes, harms. RESULTS: There was no direct evidence on the benefits or harms of screening children and adolescents for excess weight. Among 42 trials of lifestyle-based interventions to reduce excess weight (N = 6956), those with an estimated 26 hours or more of contact consistently demonstrated mean reductions in excess weight compared with usual care or other control groups after 6 to 12 months, with no evidence of causing harm. Generally, intervention groups showed absolute reductions in BMI z score of 0.20 or more and maintained their baseline weight within a mean of approximately 5 lb, while control groups showed small increases or no change in BMI z score, typically gaining a mean of 5 to 17 lb. Only 3 of 26 interventions with fewer contact hours showed a benefit in weight reduction. Use of metformin (8 studies, n = 616) and orlistat (3 studies, n = 779) were associated with greater BMI reductions compared with placebo: -0.86 (95% CI, -1.44 to -0.29; 6 studies; I2 = 0%) for metformin and -0.50 to -0.94 for orlistat. Groups receiving lifestyle-based interventions offering 52 or more hours of contact showed greater improvements in blood pressure than control groups: -6.4 mm Hg (95% CI, -8.6 to -4.2; 6 studies; I2 = 51%) for systolic blood pressure and -4.0 mm Hg (95% CI, -5.6 to -2.5; 6 studies; I2 = 17%) for diastolic blood pressure. There were mixed findings for insulin or glucose measures and no benefit for lipids. Medications showed small or no benefit for cardiometabolic outcomes, including fasting glucose level. Nonserious harms were common with medication use, although discontinuation due to adverse effects was usually less than 5%. CONCLUSIONS AND RELEVANCE: Lifestyle-based weight loss interventions with 26 or more hours of intervention contact are likely to help reduce excess weight in children and adolescents. The clinical significance of the small benefit of medication use is unclear.
引用
- O'Connor EA, Evans CV, Burda BU, et al. Screening for Obesity and Intervention for Weight Management in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2017. PMID: 28632873. doi:10.1001/jama.2017.0332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。